ArticlePLOS global public health2026
Polypharmacy and quality of life in Yemeni cancer patients undergoing chemotherapy: A cross-sectional study.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polypharmacy is common among cancer patients receiving chemotherapy due to the need for multiple supportive medications. This study assessed the prevalence of non-oncological polypharmacy and its association with quality of life (QoL) among adult cancer patients in Yemen. A cross-sectional study was conducted between 1st December 2025 and 23rd February 2026 at the National Oncology Centre in Sana'a, Yemen. Adult patients (≥18 years) receiving chemotherapy were recruited using convenience sampling. Data were collected through face-to-face interviews and medical record review. Polypharmacy was defined as the use of ≥5 non-oncological medications and excessive polypharmacy as ≥10 medications. QoL was assessed using the Arabic version of the EORTC QLQ-C30. Statistical analyses included descriptive statistics, independent-sample t-tests, and multiple linear regression using IBM SPSS Statistics version 27. Among 234 participants, 63.2% were female and 47.6% were aged 31-50 years. Polypharmacy was highly prevalent: 94.9% used ≥5 non-oncological medications and 56.4% ≥ 10. Mean global QoL was 47.9 (SD 26.7). Patients reported substantial financial difficulties (mean 82.3), fatigue (61.1), and pain (59.6). QoL did not differ significantly between excessive polypharmacy groups (mean difference -3.35; 95% CI -10.58 to 3.87; p = 0.361). In multivariable analyses, female gender independently predicted lower QoL (B = -10.13; 95% CI: -18.19 to -2.07; p = 0.014) and higher non-oncological medication use (B = 1.18; 95% CI: 0.25 to 2.10; p = 0.013). Age ≥ 51 years and illiteracy showed borderline associations with lower QoL, while all other variables, including excessive polypharmacy (≥10 non-oncological medications), were not significantly associated with QoL. Non-oncological Polypharmacy is highly prevalent among Yemeni cancer patients receiving chemotherapy. Although medication burden was substantial, it was not independently associated with QoL, whereas female gender predicted poorer outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.